These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. New perspectives in the management of Pseudomonas aeruginosa infections. Savoia D Future Microbiol; 2014; 9(7):917-28. PubMed ID: 25156380 [TBL] [Abstract][Full Text] [Related]
28. Multidrug resistance in Pseudomonas aeruginosa isolated from nosocomial respiratory and urinary infections in Aleppo, Syria. Mahfoud M; Al Najjar M; Hamzeh AR J Infect Dev Ctries; 2015 Feb; 9(2):210-3. PubMed ID: 25699497 [TBL] [Abstract][Full Text] [Related]
29. [Treatment of Pseudomonas aeruginosa septicemia in burns]. Wang DW Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi; 1987 Sep; 3(3):181-3, 237-8. PubMed ID: 3151607 [No Abstract] [Full Text] [Related]
30. Pseudomonas infections of skin: an experimental study. Singh G Int J Dermatol; 1974; 13(2):90-3. PubMed ID: 4363237 [No Abstract] [Full Text] [Related]
31. The immunoprophylaxis and immunotherapy of Pseudomonas infections in burns with polyvalent Pseudomonas aeruginosa corpuscular vaccine. Ionescu A; Meitert E; Vasiliu S; Meitert T; Milicescu S; Sima F; Savulian C Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):317-30. PubMed ID: 122594 [No Abstract] [Full Text] [Related]
32. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin]. Moroz AF; Kharitonova AM; Chanturiia TsK Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985 [TBL] [Abstract][Full Text] [Related]
35. Complicated urinary tract infection caused by Pseudomonas aeruginosa in a single institution (1999-2003). Shigemura K; Arakawa S; Sakai Y; Kinoshita S; Tanaka K; Fujisawa M Int J Urol; 2006 May; 13(5):538-42. PubMed ID: 16771722 [TBL] [Abstract][Full Text] [Related]
36. Antimicrobial activities of LCB10-0200, a novel siderophore cephalosporin, against the clinical isolates of Pseudomonas aeruginosa and other pathogens. Oh SH; Park HS; Kim HS; Yun JY; Oh K; Cho YL; Kwak JH Int J Antimicrob Agents; 2017 Dec; 50(6):700-706. PubMed ID: 28668680 [TBL] [Abstract][Full Text] [Related]
37. [Experiences in the treatment of skin infections due to Pseudomonas aeruginosa with Kasugamycin vaseline]. Kanaue F; Oura T; Tanifuji J J Antibiot B; 1967 Jun; 20(3):187-90. PubMed ID: 4965583 [No Abstract] [Full Text] [Related]
38. The role of Pseudomonas aeruginosa in infections. Neu HC J Antimicrob Chemother; 1983 May; 11 Suppl B():1-13. PubMed ID: 6413479 [TBL] [Abstract][Full Text] [Related]
39. Development of immunotherapy for infections due to Pseudomonas aeruginosa. Fisher MW J Infect Dis; 1974 Nov; 130 Suppl(0):S149-51. PubMed ID: 4138585 [No Abstract] [Full Text] [Related]
40. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection. Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]